200 unknown, 55 recruiting, 37 completed, 28 not yet recruiting. 344 Phase 2, 39 Phase 1, 15 Phase 3.
Follow camrelizumab: new trials by email Literature Review of camrelizumab trials Research Report on camrelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer H101, Camrelizumab - Pancreatic Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2025-08-07 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 33 | 2026-09-10 | 2026-09-09 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies camrelizumab with famitinib - Head and Neck Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-07-01 | 2026-06-23 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer Camrelizumab, Famitinib Malate, Chemotherapy - Cervical Cancer | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | 54 | 2026-06-30 | 2026-06-04 |
| Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer Camrelizumab, Platinum-based Chemotherapy plus PD-1 inhibitor, De-escalated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 180 | 2026-06-12 | 2026-08-28 |
| Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma Trastuzumab Rezetecan plus Camrelizumab - Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Sheng Tai | 44 | 2026-06-05 | 2026-06-10 |
| Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine - Rectal Cancer Patients | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 44 | 2026-05-20 | 2026-04-13 |
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC | Phase 2 / Phase 3 | Recruiting | Guangzhou Virotech Pharmaceutical Co., Ltd. | 66 | 2026-05-13 | 2026-05-15 |
| Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Becotatug Vedotin, Toripalimab, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-04-20 | 2026-04-29 |
| Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment Ivarmacitinib Sulfate Tablets, Camrelizumab, Fruquintinib - Refractory Metastatic Colorectal Cancer | Phase 2 | Recruiting | Renmin Hospital of Wuhan University | 33 | 2026-04-14 | 2026-10-28 |
| Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Interferon-γ, Camrelizumab - Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Hefei Cancer Hospital of the Chinese Academy of Sciences | 84 | 2026-03-20 | 2026-08-26 |
| Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy Camrelizumab + Risedronate Sodium + Chemotherapy - Breast Cancer Triple Negative Breast Cancer | Phase 2 | Active not recruiting | Harbin Medical University | 30 | 2026-03-04 | 2026-03-13 |
| A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer Camrelizumab - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Chinese PLA General Hospital | 44 | 2026-02-01 | 2026-04-14 |
| FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib - Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 86 | 2026-02-01 | 2026-01-20 |
| A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 68 | 2026-02-01 | 2026-02-09 |
| Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC Camrelizumab, Paclitaxel, carboplatin - Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms | Phase 2 | Not yet recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 50 | 2026-02-01 | 2026-02-10 |
| Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Palbociclib - Esophageal Squamour Cell Cancer | Phase 2 | Not yet recruiting | West China Hospital | 41 | 2026-01-01 | 2025-09-25 |
Showing 20 of 344. Sign in to see all of them.
Carcinoma, Hepatocellular (26) · Carcinoma, Non-Small-Cell Lung (20) · Stomach Neoplasms (18) · Triple Negative Breast Neoplasms (18) · Nasopharyngeal Carcinoma (17) · Esophageal Squamous Cell Carcinoma (16) · Breast Neoplasms (15) · Colorectal Neoplasms (12) · Esophageal Neoplasms (12) · Squamous Cell Carcinoma of Head and Neck (12) · Uterine Cervical Neoplasms (11) · Sarcoma (9) · Recurrence (7) · Hodgkin Disease (6) · Lung Neoplasms (6)
Fudan University (29) · Sun Yat-sen University (27) · Jiangsu HengRui Medicine Co., Ltd. (18) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (15) · Chinese PLA General Hospital (13) · Peking Union Medical College Hospital (12) · Peking University Cancer Hospital & Institute (10) · Tianjin Medical University Cancer Institute and Hospital (10) · Henan Cancer Hospital (9) · Zhejiang Cancer Hospital (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Hunan Cancer Hospital (6) · The First Affiliated Hospital of Zhengzhou University (6) · Chinese Academy of Medical Sciences (5) · Harbin Medical University (5)
China (297) · Russia (1) · South Korea (1)
Ding Ma (3) · Feng Wang (3) · Feng Wang, Doctor (2) · Jieqiong Liu (2) · Jingbo Wang (2) · Yanqiao Zhang, PhD (2) · Ying Wang, Ph.D, M.D. (2) · Yue He, M.D. (2) · Zhenggang Zhu (2) · Aiping Shi, PhD (1) · Bang-De Xiang, Ph.D (1) · Baoen Shan, Ph.D (1) · Baohui Han (1) · Baorui Liu, M.D & Ph.D (1)
PMID 30348638, PMID 32112738, PMID 32376724, PMID 32448804, PMID 37580352, PMID 15126782, PMID 15875784, PMID 17340590, PMID 18172173, PMID 18971936, PMID 20375404, PMID 20516446, PMID 21296855, PMID 21742485, PMID 22575238, PMID 23452187, PMID 23918952, PMID 24357284, PMID 24581682, PMID 24948466, PMID 25800393, PMID 25838374, PMID 25838375, PMID 26515495, PMID 26755520, PMID 26901407, PMID 27324428, PMID 27827318, PMID 27959684, PMID 28197365, PMID 28408606, PMID 28583311, PMID 28596308, PMID 28796558, PMID 29368638, PMID 29614760, PMID 29663291, PMID 30293387, PMID 30357594, PMID 30835255, PMID 31039052, PMID 31109809, PMID 31420358, PMID 31451841, PMID 31481761, PMID 32067509, PMID 32171104, PMID 32487569, PMID 32499235, PMID 32719455